Detalles de la búsqueda
1.
Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
J Immunother
; 41(9): 399-405, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29757889
2.
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Clin Cancer Res
; 24(18): 4416-4428, 2018 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29848573
3.
A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes.
Front Immunol
; 8: 908, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28824634
4.
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Oncoimmunology
; 6(6): e1321187, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28680759
5.
Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.
Cancer Immunol Res
; 3(11): 1201-6, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26216417
6.
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.
Clin Cancer Res
; 18(24): 6758-70, 2012 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23032743
Resultados
1 -
6
de 6
1
Próxima >
>>